OBJECTIVES: Although genital warts (GW) represent 10% or less of the total spectrum of human papillomavirus infections, they are among the most common sexually transmitted diseases causing significant psychological morbidity and substantial healthcare costs. There is no published data regarding costs of GW in Costa Rica (CR).  The aim was to describe the patterns of healthcare resource utilization (HCRU) and associated costs for female and male patients with GW in CR. METHODS: Descriptive study utilizing a Delphi panel to build consensus on patterns of HCRU for GW in CR.  The panel consisted of 11 gynecologists and 11 urologists from hospitals of the Social Security of CR.  The implementation took 5 weeks, during which the panel members received and responded to a structured questionnaire during the first round; received and reviewed data aggregated from all the responses; and responded once more to the questionnaire during a second round.   The questionnaire was based on a series of questions about the resources used in the treatment of GW, taking into account demographic data, diagnostic tests, treatment options, clinical guidelines, adverse events and complications of the current treatments, and number of outpatient visits.  The questionnaire was developed from previously published studies that used a similar methodology. The costs in local currency (2015) were obtained from the official database of the Social Security of CR and converted to US dollars. RESULTS: In women, the total cost per episode of GW was US$720.01.  The highest costs were seen in specialty consultations (US$335.37).  Pharmacological treatment accounted only for US$18.92.  The total cost per episode among men was US$534.75, mostly driven also by specialty consultations (US$305.86).  Pharmacological treatment accounted for US$14.00. CONCLUSIONS: These findings underscore the importance of implementing public health initiatives, such as education and vaccination, for the prevention of GW among women and men in CR.